Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer

Cancer Statistics, 2021

(2021) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials

(2021) A. Galvano et al.   ESMO Open

DOP08 Deep remission in paediatric Crohn’s disease is associated with increased abundance of dialister species and increased valerate

(2020) H Taylor et al.   Journal of Crohns & Colitis

Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment

(2020) Andrea Botticelli et al.   Journal of Translational Medicine

Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence

(2020) Raju K. Vaddepally et al.   Cancers

Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy

(2020) Lukas F. Mager et al.   SCIENCE

Association of Short-Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer Tumors

(2020) Motoo Nomura et al.   JAMA Network Open

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

(2020) Aurélien Marabelle et al.   LANCET ONCOLOGY

The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer

(2020) Taiki Hakozaki et al.   Cancer Immunology Research

Tumor mutational burden on cytological samples: A pilot study

(2020) Francesco Pepe et al.   CANCER CYTOPATHOLOGY

Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?

(2020) John H. Strickler et al.   CLINICAL CANCER RESEARCH

Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer

(2020) Bairavi Shankar et al.   JAMA Oncology

The short-chain fatty acid pentanoate suppresses autoimmunity by modulating the metabolic-epigenetic crosstalk in lymphocytes

(2019) Maik Luu et al.   Nature Communications

The microbiome, cancer, and cancer therapy

(2019) Beth A. Helmink et al.   NATURE MEDICINE

A defined commensal consortium elicits CD8 T cells and anti-cancer immunity

(2019) Takeshi Tanoue et al.   NATURE

Association between antibiotics use and outcome in patients with NSCLC treated with immunotherapeutics

(2019) F Huemer et al.   ANNALS OF ONCOLOGY

The diversity of gut microbiome is associated with favorable responses to anti-PD-1 immunotherapy in Chinese non-small cell lung cancer patients

(2019) Yueping Jin et al.   Journal of Thoracic Oncology

Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome

(2019) Israr Khan et al.   Pathogens

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

(2019) Satya Das et al.   Journal for ImmunoTherapy of Cancer

The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors

(2019) Andrew A. Davis et al.   Journal for ImmunoTherapy of Cancer

The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies

(2019) Brooke E. Wilson et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The Skin and Intestinal Microbiota and Their Specific Innate Immune Systems

(2019) Margaret Coates et al.   Frontiers in Immunology

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

(2018) L Derosa et al.   ANNALS OF ONCOLOGY

The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients

(2018) Vyara Matson et al.   SCIENCE

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

The Gut Microbiome as a Major Regulator of the Gut-Skin Axis

(2018) Iman Salem et al.   Frontiers in Microbiology

Current PD-L1 immunohistochemistry for non-small cell lung cancer

(2018) Andreas H. Scheel et al.   Journal of Thoracic Disease

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The role of the lung microbiota and the gut-lung axis in respiratory infectious diseases

(2018) Alexia Dumas et al.   CELLULAR MICROBIOLOGY

Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis

(2018) Yinghong Wang et al.   NATURE MEDICINE

Recovery of gut microbiota of healthy adults following antibiotic exposure

(2018) Albert Palleja et al.   Nature Microbiology

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

(2017) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bifidobacteriumcan mitigate intestinal immunopathology in the context of CTLA-4 blockade

(2017) Feng Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

(2017) V. Gopalakrishnan et al.   SCIENCE

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

(2017) Bertrand Routy et al.   SCIENCE

Product review on the Anti-PD-L1 antibody atezolizumab

(2017) Neil J. Shah et al.   Human Vaccines & Immunotherapeutics

Formation of propionate and butyrate by the human colonic microbiota

(2016) Petra Louis et al.   ENVIRONMENTAL MICROBIOLOGY

Association of three putative periodontal pathogens with chronic periodontitis in Brazilian subjects

(2016) Cristiane GONÇALVES et al.   Journal of Applied Oral Science

DADA2: High-resolution sample inference from Illumina amplicon data

(2016) Benjamin J Callahan et al.   NATURE METHODS

PD-L1 expression in human cancers and its association with clinical outcomes

(2016) Jinming Yu et al.   OncoTargets and Therapy

16S rRNA amplicon sequencing identifies microbiota associated with oral cancer, human papilloma virus infection and surgical treatment

(2016) Rafael Guerrero-Preston et al.   Oncotarget

Revised Estimates for the Number of Human and Bacteria Cells in the Body

(2016) Ron Sender et al.   PLOS BIOLOGY

Antibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of Resistances

(2016) M. P. Francino   Frontiers in Microbiology

PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?

(2016) Claud Grigg et al.   Journal for ImmunoTherapy of Cancer

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

(2015) Scott N. Gettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

(2015) Naiyer A Rizvi et al.   LANCET ONCOLOGY

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

(2015) A. Sivan et al.   SCIENCE

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

(2015) M. Vetizou et al.   SCIENCE

Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies

(2012) Anna Klindworth et al.   NUCLEIC ACIDS RESEARCH

The SILVA ribosomal RNA gene database project: improved data processing and web-based tools

(2012) Christian Quast et al.   NUCLEIC ACIDS RESEARCH

Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives

(2011) M. Joossens et al.   GUT

Enterotypes of the human gut microbiome

(2011) Manimozhiyan Arumugam et al.   NATURE

Metagenomic biomarker discovery and explanation

(2011) Nicola Segata et al.   GENOME BIOLOGY

QIIME allows analysis of high-throughput community sequencing data

(2010) J Gregory Caporaso et al.   NATURE METHODS

The effects of selected probiotic strains on the development of eczema (the PandA study)

(2009) L. Niers et al.   ALLERGY

Oral Probiotic Control Skin Inflammation by Acting on Both Effector and Regulatory T Cells

(2009) Feriel Hacini-Rachinel et al.   PLoS One

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER